Tier 2 Butyrate Assay Audit — Computational Literature Synthesis (comp-038)¶
Status: Complete first pass — 2026-05-20. Experiment folder: etc/experiments/comp-038-tier-2-butyrate-assay-audit/. Output: outputs/summary.md.
Question¶
Is there a Tier 2 butyrate quantification assay — colorimetric, enzymatic, breath-proxy, electrochemical, or other low-cost intermediate method — that can be validated against Tier 3 GC-MS for OE's stool, serum, breath, or culture-supernatant use cases?
Verdict¶
YELLOW. A ready-to-adopt simple/home colorimetric or breath-based butyrate assay did not surface. Two plausible Tier 2 candidates did surface, but both require full-text/protocol review and paired GC-MS validation before wet-lab adoption:
| Candidate | Matrix fit | Verdict | Evidence status |
|---|---|---|---|
| HPLC-UV SCFA + lactate assay for bacterial culture supernatants | Culture supernatant / engineered-strain work | YELLOW | PubMed abstract reports mM-range matrix-matched calibration and use for butyric-acid-producing bacteria; full text and OE spike-recovery still required. |
| Electrochemical fecal SCFA profiling with ANN deconvolution | Stool / fecal SCFA profiling | YELLOW | Emerging fecal SCFA platform; needs full-text butyrate-specific performance, reference-method correlation, and external validation. |
| Butyric-acid / SCFA ELISA kits | Serum/plasma/vendor-claimed matrices | RED-provisional | Vendor claims exist, but no PubMed/GC-MS validation surfaced; small-molecule specificity is a major concern. |
| Breath H2/CH4 | Breath | RED | Broad fermentation/adherence proxy, not butyrate-specific quantification. |
| Generic free-fatty-acid colorimetric kits | Serum/plasma/culture, vendor-dependent | RED | Representative FFA kit protocol excludes SCFAs including butyric acid. |
Why This Matters¶
The quantification ladder needs a cheap Tier 2 surface between visual/user-facing proxies and Tier 3 GC-MS / HPLC / LC-MS anchors. For microbiome-derived metabolites, that gap is especially painful: the genotype-informed supplement workflow can recommend butyrate-emphasis interventions for ABCG2 Q141K carriers, but it cannot yet verify butyrate delivery with a validated home or community-biolab Tier 2 assay.
comp-038 reframes that gap as two different problems:
- Culture-supernatant butyrate from engineered strains: plausible Tier 2-lab path exists via HPLC-UV, with GC-MS as anchor.
- Stool/serum/home butyrate exposure: no ready-to-adopt Tier 2 method surfaced; electrochemical fecal SCFA profiling is promising but not production-ready.
Method Summary¶
The run used the committed query strategy in inputs/query-strategy.json, fetched a PubMed title/abstract snapshot via NCBI E-utilities, then performed five Codex/GPT-5.5 in-session synthesis trajectories from outputs/codex-synthesis-packet.md. The completed run used the local Codex synthesis path and made no OpenRouter model calls.
The evidence gate was intentionally strict: PubMed title/abstract hits can surface candidates, but they cannot justify a GREEN wet-lab recommendation without full-text methods, protocol PDFs, vendor validation documents, or method-comparison data.
Key Results¶
| Result | Interpretation |
|---|---|
| PubMed snapshot: 27 queries / 74 records | Enough for a first-pass assay landscape; not a full-text review. |
| HPLC-UV candidate: PMID 23542733 | Best near-term candidate for culture-supernatant butyrate in engineered-strain / fermentation work. |
| Electrochemical fecal candidate: PMID 42041444 | Best stool-specific future direction, but still research-platform grade. |
| Breath proxy literature | Useful for fermentation activity, not butyrate quantification. |
| Generic FFA colorimetric kits | False-friend class; representative protocol excludes acetic, propionic, and butyric acid. |
Impact on Experimental Priorities¶
This does not unlock a home butyrate assay today. It does tighten the next experimental move:
- Keep GC-MS as the Tier 3 anchor for butyrate.
- For engineered-strain / culture-supernatant work, run a small paired validation of HPLC-UV against GC-MS using sodium-butyrate standards and OE-relevant culture matrices.
- For stool work, do a full-text and protocol review of the electrochemical fecal SCFA platform before spending on hardware or adaptation.
- Do not spend on breath hydrogen/methane or generic FFA colorimetric kits for butyrate quantification.
For validation-experiments.md §1.14, this means the butyrate dose-response arm still needs a Tier 3 analytical anchor if concentration verification becomes load-bearing. HPLC-UV may become a cheaper intermediate check for culture-supernatant development, but not for the cellular dose-response arm without matrix validation.
Limitations¶
- PubMed results are title/abstract/citation metadata, not full-text validation.
- Vendor and patent searches were targeted, not exhaustive.
- Commercial ELISA claims remain unverified and should not drive spend.
- No non-English corpus pass was run because this specific scope is analytical-chemistry-heavy and Stage 1 was not sparse; revisit if full-text/vendor follow-up stalls.
- The N=5 trajectories were performed in one Codex session to avoid OpenRouter spend, not by five independent paid model calls.
Next Step¶
Run a focused full-text/protocol verification pass on PMID 23542733 and PMID 42041444, plus a vendor protocol audit for any butyric-acid/SCFA ELISA claims. If one candidate survives, design a small paired validation with sodium-butyrate spike/recovery and 10-20 real samples measured by the candidate Tier 2 method plus GC-MS.
Full-text verification — completed 2026-06-01¶
The full-text pass above was run (multilingual; English + Chinese analytical-chemistry sources). Outcome — one candidate survives, two fail the full-text Tier-2 gate:
| Candidate | Resolves to | Verdict | Reason |
|---|---|---|---|
| HPLC-UV (PMID 23542733) | De Baere et al. 2013, J Pharm Biomed Anal 80:107–115 | ✅ SURVIVES (community-biolab tier) | Validated on bacterial culture supernatant (OE's near-term matrix), linear 0.5–50 mM, no derivatization (direct UV 210 nm), butyrate resolved from acetate/propionate/lactate. Gate-keeper is the HPLC instrument — not home/kitchen tier, but decentralizable to a community biolab. |
| Electrochemical + ANN (PMID 42041444) | Gu et al. 2026, Biosensors 16(4):223 | ❌ FAILS | Vendor-locked hardware (VidaBio chip + potentiostat), dual derivatization (esterification + dissociation), and butyrate specificity depends on an unreleased ANN adopters must retrain against their own GC-MS — making GC-MS a prerequisite, not a replacement. Fecal-only matrix. (Real paper, GC-MS-validated R²=0.998 — kept as a citation, not a Tier-2 option.) |
| SCFA/butyrate ELISA kits | US Biological / Aviva / LSBio etc. | ❌ FAILS (confirms RED) | Vendor dynamic range ~pg/mL (≈nM), 5–6 orders of magnitude below mM culture/colonic butyrate; specificity on an 88-Da analyte unvalidated against GC-MS in a real SCFA matrix. |
[TRANSLATION NOTE] Chinese analytical literature (短链脂肪酸 HPLC / 电化学检测) corroborated the load-bearing claim with no disagreement: most fecal-matrix SCFA-HPLC methods require pre-column derivatization (e.g. 3-nitrophenylhydrazine) because SCFAs lack a chromophore; De Baere's direct-UV-at-210 nm approach is the distinguishing feature that avoids derivatization, at the cost of non-selective absorbance (hence the medium-blank requirement).
Operationalized as a tracked wet-lab gate: validation-experiments.md §1.31 — HPLC-UV vs. GC-MS spike/recovery on culture supernatant, with GREEN/YELLOW/RED success criteria. The empirical spike/recovery remains wet-lab gated (OE is Phase 0; needs partner-CRO / community-biolab HPLC-UV + GC-MS access); the candidate-selection question is now closed.